Abstract
Tetrahydropapaveroline (THP) concentrations were measured in the urine of Parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy, using a method that employs a separation scheme that selectively isolates THP from urine and utilizes the Pictet-Spengler condensation of THP with formaldehyde combined with high-performance liquid chromatography for identification and determination. The mean (+/- S.D.) recoveries of THP from normal urine with 0.2 pmol/ml added and from Parkinsonian patients' urines with 0.5 pmol/ml added were 48.6 +/- 5.7 and 44.6 +/- 3.1%, respectively. Three Parkinsonian patients who were receiving either 250, 750 or 1000 mg of L-dopa (as Sinemet) daily had 24-h urinary THP excretion levels of 989, 1017 and 1600 pmol, respectively.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adsorption
-
Aluminum Oxide
-
Antiparkinson Agents / pharmacokinetics*
-
Antiparkinson Agents / therapeutic use
-
Carbidopa / pharmacokinetics*
-
Carbidopa / therapeutic use
-
Cation Exchange Resins
-
Chromatography, High Pressure Liquid
-
Chromatography, Ion Exchange
-
Drug Combinations
-
Electrochemistry
-
Humans
-
Levodopa / pharmacokinetics*
-
Levodopa / therapeutic use
-
Parkinson Disease / drug therapy
-
Parkinson Disease / urine*
-
Resins, Synthetic
-
Silanes
-
Tetrahydropapaveroline / urine*
Substances
-
Antiparkinson Agents
-
Cation Exchange Resins
-
Drug Combinations
-
Resins, Synthetic
-
Silanes
-
carbidopa, levodopa drug combination
-
octadecylsilane
-
Levodopa
-
Tetrahydropapaveroline
-
Bio-Rex 70
-
Aluminum Oxide
-
Carbidopa